China is the bigger Alzheimers Dignostic market: $169 Mn against $38 Mn in 2023, about 4.4 times as large.
India grows faster: 9.9% a year, against 8.4%. The gap still grows from $131 Mn to $280 Mn by 2033.
Clinical research: 148 active trials in China, 7 in India.
| Measure |  China |  India |
|---|---|---|
| Market size, 2023 | $169 Mn | $38 Mn |
| Market size, 2033 projected | $378 Mn | $98 Mn |
| Growth a year (CAGR) | 8.4% | 9.9% |
| Money added, 2023–2033 | $209 Mn | $60 Mn |
| Share of the world market | 8% | 1.8% |
| Size rank of 24 countries | #2 | #12 |
| Market per person, 2023 | $0.12 | $0.03 |
| Active clinical trials | 148 | 7 |
| Full report | China report | India report |
Year by year, 2023 to 2033
China India · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Alzheimers Dignostic, China or India?
China is the bigger Alzheimers Dignostic market: $169 Mn against $38 Mn in 2023, about 4.4 times as large.
Which grows faster in Alzheimers Dignostic, China or India?
India grows faster: 9.9% a year, against 8.4%. The gap still grows from $131 Mn to $280 Mn by 2033.
More Alzheimers Dignostic comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.